Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR–ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction

References

• Druker BJ, Guilhot F, O’Brien SG, . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 2009;114:5426–5435.
   PubMed Web of Science ®Google Scholar
• Khorashad JS, Anand M, Marin D, . The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006;20:658–663.
   PubMed Web of Science ®Google Scholar
• Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011;25:7–22.
   PubMed Web of Science ®Google Scholar
• Ernst T, La Rosée P, Müller MC, . BCR-ABL mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am 2011;25:997–1008.
   PubMed Web of Science ®Google Scholar
• Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 2006;125:93–106.
   PubMedGoogle Scholar
• Bengió RM, Riva ME, Moiraghi B, . Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study. Leuk Lymphoma 2011;52:1720–1726.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol 2010;47:344–353.
   PubMed Web of Science ®Google Scholar
• Wittwer CT, Reed GH, Gundry CN, . High resolution genotyping by amplicon melting analysis using LC Green. Clin Chem 2003;9: 853–860.
   Web of Science ®Google Scholar
• Yin CC, Cortes J, Galbincea J, . Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci 2010;101: 2005–2010.
   PubMed Web of Science ®Google Scholar
• Gruber FX, Ernst T, Kiselev Y, . Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment. Clin Chem 2010;56:469–473.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, . Evolving concepts in the management of chronic myeloid leukemia recommendations from an expert panel on behalf of the Erropean LeukemiaNet. Blood 2006;108:1809–1817.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Kaeda J, Branford S, . International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423–1432.
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, . High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472–3475.
   PubMed Web of Science ®Google Scholar
• Mathisen M, Kantarjian H, Cortes J, . Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica 2011;96:347–349.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Wals S, . Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompained by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276–283.
   PubMed Web of Science ®Google Scholar
• Clayton SJ, Scott FM, Walker J, . K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplificacion. Clin Chem 2000;46:1929–1938.
   PubMed Web of Science ®Google Scholar
• Doi Y, Sasaki D, Terada CH, . High-resolution melting analysis for a reliable and two-step scanning of mutations in the tyrosine kinase domain of the chimerical bcr-abl gene. Int J Hematol 2009;90:37–43.
   PubMed Web of Science ®Google Scholar
• Poláková KM, Lopotová T, Klamová H, . High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain. Leuk Res 2008;32:1236–1243.
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodogy for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Parkinson I, . Real time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926–2932.
   PubMed Web of Science ®Google Scholar
• Olsson-Stromberg U, Hermansson M, Lundán T, . Molecular monitoring and mutation analysis of patients with advanced phse CML and Ph+ ALL receiving dasatinib. Eur J Haematol 2010;85:399–404.
   PubMed Web of Science ®Google Scholar
• Wang I, Knight K, Lucas C, . The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL mutations in imatinib treated patients with chronic myeloid leukemia. Haematologica 2006;91:235–239.
   PubMed Web of Science ®Google Scholar
• Härtel N, Klag T, Hochhaus A, . Overexpression of the IL3/IL5/GM-CSFRB as potential mechanism leading to survival factor activation in response to ABL inhibitors treatment. Haematologica 2008;93(Suppl. 1): Abstract 382.
   PubMed Web of Science ®Google Scholar
• Hanfstein B, Muller MC, Kreil S, . Dynamics of mutant BCR-ABL positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 2011;96:360–366.
   PubMed Web of Science ®Google Scholar